Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 655.15

-0.4%

12:02 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biotechwantabe who wrote (3085)	8/22/2020 11:22:29 AM
From: Miljenko Zuanic	Read Replies (2) of 3557

Yes, indeed it is significant. First, other covid nAbs developers do not have SC formulation (as prophylactic, few days dosing to rise nAbs level to therapeutic one), Second, if for instance dose is 10 mg/Kg (800 mg for 80 Kg person), how will you do SC injection? At 50mg/mL conc (standard) it is 16 mL injection. For 2 mg/Kg it is 3.2 mL!!! As note, terapeutic Ebola dose is 50 mg/Kg, for COVID-MERS they studied 25 & 50 mg/Kg. So, for coronavirus CoV-19 they have MUCH POTENT cocktail, or they developed formulation with much higher concentration. Roche was not stupid when they signed deal with them. Mr. Market have NO IDEA, as one should not be surprised.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next